Program
eltrombopag
Also written as “Eltrombopag”, “SB497115” and “Eltrombopag olamine”.
Its studies are mostly in Purpura, Thrombocytopenic, Idiopathic · Thrombocytopenia · Anemia, Aplastic · Purpura · Hepatitis C, Chronic, led by 4 companies.
Drug pageEltrombopag: every studyAll 135 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| GlaxoSmithKlineits history only | 290 open or running | phase 4since Jan 7, 2010 | Feb 1, 2005 | none ahead |
| Novartisits history only | 182 open or running | phase 4since Oct 4, 2013 | Jul 10, 2006 | Apr 22, 2033phase 2 · NCT07660172 |
| Bristol-Myers Squibbits history only | 10 open or running | phase 1since Jun 20, 2023 | Jun 20, 2023 | none ahead |
| Renata | 11 open or running | phase 2since Jul 6, 2024 | Jul 6, 2024 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Renata only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 6, 2024First study: phase 2 study in Purpura, Thrombocytopenic, IdiopathicFirst studyNCT06531018 · 100 planned · Bangladesh
TargetBeta
“Thrombopoietin receptor agonist; Thrombopoietin receptor agonist”ChEMBL 37, by rule
Other programs on MPL
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| romiplostimrule | Amgen | phase 4 | 38 |
| avatrombopagrule | Eisai | phase 4 | 25 |
| hetrombopag olaminerule | Jiangsu HengRui Medicine | phase 3 | 15 |
Studies
The one study Renata leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06531018Purpura, Thrombocytopenic, Idiopathic · Bangladesh | 2 | Recruiting | Aug 31, 2025 | 100 |
How it is read
Names in the registry
- “Eltrombopag”, 19 entries
- “eltrombopag”, 15 entries
- “SB497115”, 3 entries
- “Eltrombopag olamine”, 2 entries
- “Eltrombopag 25 MG”, 1 entry
Conditions, from the studies’ own filings
- Purpura, Thrombocytopenic, Idiopathic, 15 studies
- Thrombocytopenia, 8 studies
- Anemia, Aplastic, 6 studies
- Purpura, 5 studies
- Hepatitis C, Chronic, 4 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.